A small genomic study of patients with chemoradiation-treated urothelial carcinoma of the bladder found similar mutation patterns between primary and recurrent tumors.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Related Links:

Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

ConclusionsThe results of our study demonstrate that miR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.

Source: Life SciencesCategory: Biology Source Type: research

Contributors : Deepika Dhawan ; Noah M Hahn ; Jos é A Ramos-Vara ; Deborah W KnappSeries Type : Expression profiling by high throughput sequencingOrganism : Canis lupus familiarisRNA-seq was used to identify basal and luminal subtypes in canine bladder cancer. In addition to larger gene-sets, a smaller panel of genes was developed to stratify canine samples into either basal or luminal subtype prospectively. Immune signature patterns were queried in basal and luminal subtypes.

Source: GEO: Gene Expression OmnibusCategory: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Canis lupus familiaris Source Type: research

In this study, TRIM65 was first screened as an important oncogenic factor of UCB from the Cancer Genome Atlas (TCGA) database and was validated by a large cohort of clinical UCB tissues.

Source: Cancer LettersCategory: Cancer & Oncology Authors: Tags: Original Articles Source Type: research

ConclusionsNon-urothelial cancers of the urinary bladder are rare and mostly lack established protocols for treatment. The prognosis of most of these tumors is poor because they are usually advanced at the time of diagnosis. A multimodal treatment approach should be considered to improve outcomes.

In the last decade, immunotherapy has completely changed the therapeutic armamentarium of patients with genitourinary tumors. In particular, the approval of anti-Programmed-death-1 (PD-1) agents in patients with renal cell carcinoma (RCC) and bladder cancer (BC) has increased their life expectancy, with a generally tolerated toxicity profile. On the contrary, patients with prostate cancer (PCa) seem to scarcely benefit from this strategy.

Source: Critical Reviews in Oncology HematologyCategory: Cancer & Oncology Authors: Source Type: research

Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising que…

Author: BeaconMedIC
Added: 07/31/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

This study aimed to investigate the effects of juglone on the human bladder carcinoma cell lines TCC-SUB and RT-4 in monolayer and spheroid cultures. Cells were treated with juglone at 24, 48, and 72 h of incubation. The activity of caspase-3 was detected in vitro using a caspase-3 colorimetric assay kit according to the manufacturer’s instructions. The bromodeoxyuridine (BrdU) labeling index was used to determine the cells of the synthesis phase. The terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay was used to determine the death of cells in both the monolayer and spheroid cultures. The control …

Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy instead of chemotherapy for muscle-invasive t…

Author: BeaconMedIC
Added: 07/27/2018

Source: Oncology TubeCategory: Cancer & Oncology Source Type: podcasts

Conditions:   Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Biological: Durvalumab;   Radiation: External Beam Radiation Therapy;   Biological: Tremelimumab Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI) Not yet recruiting

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image